Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X

被引:24
作者
Li, Jian-Jun [1 ]
Wang, Ying
Nie, Shao-Ping
Li, Qian
Li, Yi-Shi
Huang, Yuan
Hui, Ru-Tai
机构
[1] Chinese Acad Med Sci, Fu Wai Hosp, Peking Union Med Coll, Dept Cardiol, Beijing 100037, Peoples R China
[2] Zhengzhou Univ, Sch Med, Affiliated Hosp 1, Dept Geriatr, Zhengzhou 450000, Peoples R China
[3] Capital Univ Med Sci, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China
[4] Peking Univ, Undergrad Coll Life Sci, Beijing 100023, Peoples R China
关键词
Xuezhikang; lipid profile; C-reactive protein; interleukin-6; endothelin-1; exercise test; cardiac syndrome X;
D O I
10.1016/j.ijcard.2006.11.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have demonstrated that Xuezhikang, an extract of cholestin, available from Chinese red yeast rice, could effectively modify lipid profile. The present study was undertaken to investigate whether Xuezhikang could modify endothelin- 1 ( ET- 1), interleukin- 6 ( IL- 6), high- sensitivity C- reactive protein ( CRP) and exercise- induced ischemia in patients with cardiac syndrome X ( CSX). Thirty- six patients with CSX were randomly assigned to 1200 mg/ d of Xuezhikang or placebo group ( n= 18 respectively). Blood samples were drawn at day 0 and day 90 for measuring above parameters. The treadmill exercise tests and subjective feelings were also assessed at day 0 and day 90. The data showed that Xuezhikang therapy resulted in significant reductions in total cholesterol ( TC, 19%), low- density lipoprotein cholesterol ( LDL- C) ( 26%), and triglycerides ( TG) compared with baseline ( 16%, p<0.01 respectively). The data also showed that Xuezhikang led significantly to reductions in median and log- CRP levels ( 38% and 44%, p<0.01 respectively), IL- 6 ( 20%, p<0.01), and ET- 1 ( 47%, p<0.01) compared with baseline. The exercise duration, and time to 1 mm ST- segment depression was significantly prolonged after Xuezhikang therapy ( 9% and 6%, p<0.05 respectively) accompanied by improvement of subjective feelings. Data suggested that the benefit of Xuezhikang resulted in significant modification vascular function by reduction of ET- 1, inflammatory markers and LDL cholesterol, which may be clinically important for patients with CSX. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:82 / 84
页数:3
相关论文
共 9 条
  • [1] Li Jian-Jun, 2005, Clinica Chimica Acta, V352, P127
  • [2] Li Jian-Jun, 2004, Heart Lung Circ, V13, P173, DOI 10.1016/j.hlc.2004.02.005
  • [3] Is slow coronary flow associated with inflammation?
    Li, JJ
    Xu, B
    Li, ZC
    Qian, J
    Wei, BQ
    [J]. MEDICAL HYPOTHESES, 2006, 66 (03) : 504 - 508
  • [4] Li JJ, 2005, CHINESE MED J-PEKING, V118, P1817
  • [5] Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
    Li, JJ
    Hu, SS
    Fang, CH
    Hui, RT
    Miao, LF
    Yang, YJ
    Gao, RL
    [J]. CLINICA CHIMICA ACTA, 2005, 352 (1-2) : 217 - 224
  • [6] Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia
    Li, JJ
    Chen, MZ
    Chen, X
    Fang, CH
    [J]. CLINICAL CARDIOLOGY, 2003, 26 (10) : 472 - 476
  • [7] Circadian variation in ischemic threshold in patients with stable angina: Relation to plasma endothelin-1
    Li, JJ
    Huang, CX
    Fang, CH
    Chen, F
    Jiang, H
    Tang, QZ
    Li, GS
    [J]. ANGIOLOGY, 2002, 53 (04) : 409 - 413
  • [8] Relation between C reactive protein concentrations and coronary microvascular endothelial function
    Teragawa, H
    Fukuda, Y
    Matsuda, K
    Ueda, K
    Higashi, Y
    Oshima, T
    Yoshizumi, M
    Chayama, K
    [J]. HEART, 2004, 90 (07) : 750 - 754
  • [9] Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X)
    Tousoulis, D
    Davies, GJ
    Asimakopoos, G
    Homaei, H
    Zouridakis, E
    Ahmed, N
    Kaski, JC
    [J]. CLINICAL CARDIOLOGY, 2001, 24 (04) : 301 - 304